Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company focused on human genetics and personalized products, has published its issuer report for the first half of 2026. The report reveals a mixed financial performance but highlights positive developments in the company's core business areas and strategic initiatives.
Consolidated revenue for H1 2026 amounted to EUR 25.7 million, a 7% decline from EUR 26.5 million in the prior-year period. This decrease was primarily attributed to lower volumes in the pharmaceutical and medical device trading segment due to regulatory changes. However, the DNA analysis and personalized products segment posted positive revenue growth, underscoring the resilience of Novogenia's core focus. CEO Dr. Daniel Wallerstorfer commented, “The financial performance in the first half of 2026 did not meet our expectations in all business areas... However, we are encouraged by the positive year-on-year development of our core business in DNA analyses and personalized health products.”
Cost-saving measures in materials, personnel, and other operating expenses led to an improvement in operating profit of approximately EUR 2.7 million. Despite this, operating result (EBIT) improved only 4.1% to EUR -4.7 million, as prior-year one-time effects boosted other operating income. Consolidated net income was EUR -2.1 million, compared to EUR 2.0 million in the previous year, which had benefited from a significantly higher financial result. As of June 30, 2026, Novogenia held EUR 39.8 million in cash and cash equivalents, down from EUR 71.9 million but still providing a solid financial position to drive further development.
Strategically, Novogenia made significant progress in H1 2026. The collaboration with 10X Health Systems was expanded through a joint product pipeline, and the enhanced Methylation Test MGT Plus was launched in the U.S. market. In collaboration with G42 in Abu Dhabi, preparations for a Middle East market launch advanced, including product adaptations and Halal certification. The company also launched the Multi-Cancer Check and established a new software platform for its NovoDaily product line. Construction began on a new company site in Hallwang near Salzburg, covering over 9,300 square meters, with completion planned for early 2028. Additionally, the renaming from Darwin AG to Novogenia AG was implemented in July 2026, consolidating brand identity.
Novogenia will engage with investors and industry stakeholders at several upcoming conferences. These include the 5th Zurich Investor Day on September 29, 2026, the Abu Dhabi Future Health Summit from October 20–22, 2026, the ODDO BHF Autumn Round Table on October 22, 2026, and the Deutsches Eigenkapitalforum 2026 from November 23–25, 2026. These events will showcase Novogenia's personalized health solutions and provide opportunities for investor discussions.
For more information, visit https://novogenia.com/novogenia-ag. The original release can be viewed on www.newmediawire.com.
This news matters for the healthcare industry as it highlights the challenges and opportunities in personalized prevention and genetic analysis. Novogenia's ability to grow its core business despite regulatory hurdles and platform algorithm changes demonstrates the increasing demand for personalized health solutions. The company's strategic partnerships and product launches, particularly in the U.S. and Middle East, signal a trend toward global expansion in genetic-based healthcare. For readers, this underscores the growing availability of personalized health products and the importance of genetic insights in preventive care. As Novogenia continues to navigate a dynamic market, its progress will be closely watched by investors and industry stakeholders alike.
